AN INACTIVATED VACCINE BASED ON A GLYCOPROTEIN E-NEGATIVE STRAIN OF BOVINE HERPESVIRUS-1 INDUCES PROTECTIVE IMMUNITY AND ALLOWS SEROLOGICAL DIFFERENTIATION

被引:98
作者
KAASHOEK, MJ [1 ]
MOERMAN, A [1 ]
MADIC, J [1 ]
WEERDMEESTER, K [1 ]
MARISVELDHUIS, M [1 ]
RIJSEWIJK, FAM [1 ]
VANOIRSCHOT, JT [1 ]
机构
[1] DLO,ID,INST ANIM SCI & HLTH,DEPT HERD HLTH PATHOL & EPIDEMIOL,8200 AB LELYSTAD,NETHERLANDS
关键词
BOVINE HERPESVIRUS 1; GLYCOPROTEIN E-NEGATIVE; MARKER VACCINE;
D O I
10.1016/0264-410X(95)98254-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The bovine herpesvirus 1 (BHV1) strain Za is a conventionally attenuated strain with a 2.7kb deletion that encompasses the complete coding region for glycoprotein E (gE). This gE-negative strain was used as whole-virus antigen in an inactivated virus vaccine. Three different antigen concentrations of this vaccine w ere evaluated for safety and efficacy in a vaccination-challenge experiment in calves. No adverse effects were observed in any of the calves vaccinated with the gE-negative vaccines. Calves given the vaccine with the highest antigen concentration were adequately protected against challenge; clinical symptoms were virtually absent and challenge virus shedding, was significantly reduced as compared with unvaccinated calves. We developed a sensitive blocking enzyme-linked immunosorbent assay (ELISA) to detect antibodies against gE. After vaccination, calves did not produce antibodies against gE, but these antibodies were detectable within 2 weeks after challenge both in vaccinated and in unvaccinated calves. These results demonstrate the efficacy of a gE-negatiue inactivated BHV1 vaccine and the detectability of antibodies against gE after infection. The combined use of the marker vaccine and the gE-blocking ELISA makes it possible to differentiate between vaccinated animals and infected animals. This possibility may be very useful in BHV1 control programmes.
引用
收藏
页码:342 / 346
页数:5
相关论文
共 13 条
[1]   ROUND-TABLE ON INFECTIOUS BOVINE-RHINOTRACHEITIS INFECTIOUS PUSTULAR VULVOVAGINITIS VIRUS-INFECTION DIAGNOSIS AND CONTROL [J].
ACKERMANN, M ;
BELAK, S ;
BITSCH, V ;
EDWARDS, S ;
MOUSSA, A ;
ROCKBORN, G ;
THIRY, E .
VETERINARY MICROBIOLOGY, 1990, 23 (1-4) :361-363
[2]   EFFICACY OF A DELETION MUTANT BOVINE HERPESVIRUS-L (BHV-1) VACCINE THAT ALLOWS SEROLOGIC DIFFERENTIATION OF VACCINATED FROM NATURALLY INFECTED ANIMALS [J].
FLORES, EF ;
OSORIO, FA ;
ZANELLA, EL ;
KIT, S ;
KIT, M .
JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, 1993, 5 (04) :534-540
[3]   SAFETY AND EFFICACY OF LIVE AND INACTIVATED INFECTIOUS BOVINE-RHINOTRACHEITIS VACCINES [J].
FRERICHS, GN ;
WOODS, SB ;
LUCAS, MH ;
SANDS, JJ .
VETERINARY RECORD, 1982, 111 (06) :116-122
[4]   TRUNCATED BOVINE HERPESVIRUS-1 GLYCOPROTEIN I (GPI) INITIATES A PROTECTIVE LOCAL IMMUNE-RESPONSE IN ITS NATURAL HOST [J].
GAO, Y ;
LEARY, TP ;
ESKRA, L ;
SPLITTER, GA .
VACCINE, 1994, 12 (02) :145-152
[5]  
Gibbs E. P. J., 1977, Veterinary Bulletin, V47, P317
[6]   A CONVENTIONALLY ATTENUATED GLYCOPROTEIN E-NEGATIVE STRAIN OF BOVINE HERPESVIRUS TYPE-1 IS AN EFFICACIOUS AND SAFE VACCINE [J].
KAASHOEK, MJ ;
MOERMAN, A ;
MADIC, J ;
RIJSEWIJK, FAM ;
QUAK, J ;
GIELKENS, ALJ ;
VANOIRSCHOT, JT .
VACCINE, 1994, 12 (05) :439-444
[7]  
LITTELVANDENHUR.SV, 1993, VACCINE, V11, P25
[8]  
MILLER JM, 1984, AM J VET RES, V45, P790
[9]  
MITCHELL D, 1974, CAN VET J, V15, P148
[10]  
PASTORET PP, 1980, INFECT IMMUN, V29, P483